The role of S-1 in the treatment of gastric cancer
2008
The role of S-1 in the treatment of gastric cancer
Sample size: 305
publication
Evidence: high
Author Information
Author(s): Kubota T
Primary Institution: Center for Comprehensive and Advanced Medicine, Keio University Hospital
Hypothesis
S-1 is a potent antitumour drug in gastric cancer.
Conclusion
S-1 has demonstrated efficacy in both adjuvant and primary settings for gastric cancer treatment.
Supporting Evidence
- S-1 was shown to have improved tumour-selective toxicity compared to 5-FU alone.
- The overall response rate in one phase II study was 44%.
- The median survival time in all patients was 207 days.
- The combination of S-1 and DDP showed a significant increase in overall survival compared to S-1 alone.
Takeaway
S-1 is a medicine that helps treat stomach cancer and has been shown to work well after surgery.
Methodology
The study involved multiple phase II and III trials assessing the efficacy and safety of S-1 in gastric cancer patients.
Limitations
The planned sample size was not achieved due to slow recruitment.
Participant Demographics
Patients with advanced gastric cancer, including those who had not previously received chemotherapy.
Statistical Information
P-Value
0.0366
Confidence Interval
95% CI, 30–59%
Statistical Significance
p=0.0366
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website